April 29, 2016
Fewer perioperative blood transfusions have occurred for oncologic abdominal surgery over the last 9 years, according to results of a retrospective review of a population-based registry.
“The relative risks and benefits of allogeneic blood transfusion are particularly complex for the oncological surgery patient,” Giorgos C. Karakousis, MD, FACS, assistant professor of surgery at the Hospital at the University of Pennsylvania and chair of the cancer committee at the Abramson Cancer Center in the Perelman School of Medicine, and colleagues wrote. “Transfusion-related immunomodulation has been recognized for more than 30 years, when it was observed that renal allograft survival was improved with preoperative blood transfusion. Whether the immunosuppressive effects of allogeneic transfusion are associated with an increased risk of cancer recurrence has not been definitely established, although associations in a variety of abdominal malignant tumors have been observed.”